VascularBarrier & vessel biology
Partner with us Precision medicine for Alzheimer's disease
Right patient.
Right biology.
Better outcomes.
Precision-AD discovers biologically distinct forms of Alzheimer's disease—then turns those insights into targeted therapeutics, companion diagnostics, and smarter clinical trials.
Vascular
Immune
Synaptic
ADbiology
Human data firstMechanism-led discoveryTranslational by design
01 — The premise
Alzheimer's is not one disease.
We shouldn't treat it like one.
Today's one-size-fits-all approach obscures the biology that determines who responds, who does not, and which therapeutic strategy belongs in which patient.
SynapticNeuronal resilience & signaling
ImmuneInflammatory signaling
02 — Our platform
From human biology
to precision assets.
We integrate human multi-omic and clinical data to find the biology hidden inside an Alzheimer's diagnosis—then design the therapeutic and diagnostic paths together.
01⌁
Discover
Find reproducible, disease-relevant signals across harmonized genomics, proteomics, imaging, and clinical phenotypes.
- Human-first evidence
- Multi-cohort replication
02◎
Stratify
Resolve biologically coherent patient subgroups and the biomarkers that identify them.
- Mechanistic subtypes
- Response hypotheses
03
Translate
Advance targeted interventions, companion diagnostics, and enrichment strategies around the same biology.
- Therapeutic programs
- Trial-ready biomarkers
GenomicsProteomicsImagingNeuropathologyClinical data
The difference
Designed to close
the translation gap.
Human evidence
at the center
Programs begin with disease biology observed in people—not a model looking for relevance.
Therapeutic + diagnostic
by design
We build the intervention and the patient-selection strategy as one translational system.
Value across the
development lifecycle
From target discovery through clinical enrichment, every layer sharpens the probability of success.
03 — Pipeline
A focused path
to patient impact.
Our lead programs extend beyond amyloid and tau to target fundamental biological drivers of Alzheimer's disease, backed by robust human evidence and offering a clear, actionable path to therapeutic intervention.
ProgramBiologyModalityDiscoveryValidationPreclinical
P-AD01Lead therapeuticVascular–immune axisSmall molecule
P-ADXCompanion diagnosticPatient subtype signatureMulti-marker assay
P-AD02Neuronal therapeuticNeuronal resilienceSmall molecule
Complete In progress Planned
04 — News & insights
Advancing the science
behind precision medicine.
Recent academic research from Timothy Hohman's group continues to define the role of vascular biology in Alzheimer's disease.
Multi-omic expression of the VEGF family relates to Alzheimer's disease across diverse populations
The largest multi-omic study of VEGF genes in diverse Alzheimer's populations replicated associations between FLT1 and FLT4 protein abundance and greater neuropathology.
Read the publicationVascular endothelial growth factor receptor-1 (FLT1) interactions with amyloid-beta in Alzheimer's disease: A putative biomarker of amyloid-induced vascular damage
Higher FLT1 levels in cerebrospinal fluid and post-mortem brain tissue were associated with greater tau pathology, particularly among amyloid-positive individuals.
Read the publication05 — Founding team
Built at the intersection
of data and disease.
Co-founder & CEO
Annah Sclafani, PhD
Neuropharmacologist and data scientist using computational approaches to accelerate drug discovery and advance novel therapeutic strategies through translational science and human biology.
Co-founder and Lead Scientific Advisor
Timothy Hohman, PhD
Human geneticist and Alzheimer's researcher at the forefront of multi-omic discovery, revealing disease mechanisms, biomarkers, and precision therapeutic targets.
Start a conversation
Let's build the next
generation of Alzheimer's care.
We're seeking biopharma, diagnostic, research, and investment partners who share our conviction that better patient selection can unlock better outcomes.
Contact the founding team